← Human Trials & Peer-Reviewed Studies
Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
Plain-language guide to PMID 12619939 (2003): placebo-controlled randomized controlled trial study of Teriparatide and Parathyroid Hormone (PTH 1-84) in 101 women, osteoporosis and bone density.
Key Facts
- PMID
- 12619939
- Journal
- Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- Zanchetta JR et al. (9 authors)
- DOI
- 10.1359/jbmr.2003.18.3.539
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teriparatide and Parathyroid Hormone (PTH 1-84) in the context of osteoporosis and bone density in this randomized controlled trial publication.
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo (n = 35) or teriparatide 20 microg (n = 38) or 40 microg (n = 28).
The researchers obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
Who Took Part
The abstract describes 101 women taking part.
PubMed indexes the participants as middle-aged adults and older adults, women only.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
A placebo (an inactive look-alike) gave the Teriparatide group a baseline to be compared against.
What Was Measured
This cross-sectional study assessed parameters of cortical bone quality by peripheral quantitative computed tomography (pQCT) in the nondominant distal radius of 101 postmenopausal women with osteoporosis who were randomly allocated to once-daily, self-administered subcutaneous injections of placebo (n = 35) or teriparatide 20 microg (n = 38) or 40 microg (n = 28).
The researchers obtained measurements of moments of inertia, bone circumferences, bone mineral content, and bone area after a median of 18 months of treatment.
The subject headings attached to it are Bone and Bones, Cross-Sectional Studies, Osteoporosis, Postmenopause and Teriparatide.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Teriparatide and Parathyroid Hormone (PTH 1-84) in 101 women in people with osteoporosis and bone density.
The publication is from 2003 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.
More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, Osteoporosis and bone density research.
Our Notes on the Compounds
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
- Osteoporosis and bone density research
- Teriparatide in the library
- Parathyroid Hormone (PTH 1-84) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.